Chris LaVictoire Mahai bought $11k of THQ
director at abrdn Healthcare Opportunities Fund. 568 shares at an average of $18.49, traded Jul 16, 2026, filed Jul 20, 2026.
Score components
- +15RoleDirector
- 0Trade size$11k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-26-085023, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 16, 2026 | POpen-market purchase Common Stock | +568 | $18.49 | $11k | 568 | Jul 20, 2026 |
Related signals
Other insiders at abrdn Healthcare Opportunities Fund and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | THQbuy abrdn Healthcare Opportunities Fund | Rose DiMartino director | $21k 1,000 shares | - | |
| 25Weak | THQbuy abrdn Healthcare Opportunities Fund | Kathleen Goetz director | $12k 600 shares | +109% | |
| 31Weak | abrdn Healthcare Opportunities Fund | Todd Reit director | $18k 1,000 shares | - | |
| 31Weak | abrdn Healthcare Opportunities Fund | Bill Maher director | $18k 1,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.